RBC Bioscience (ROCO:6848) Debt-to-Asset : 0.65 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is RBC Bioscience Debt-to-Asset?

RBC Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$74.8 Mil. RBC Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$412.6 Mil. RBC Bioscience's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was NT$753.8 Mil. RBC Bioscience's debt to asset for the quarter that ended in Dec. 2023 was 0.65.

RBC Bioscience Debt-to-Asset Historical Data

The historical data trend for RBC Bioscience's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RBC Bioscience Debt-to-Asset Chart

RBC Bioscience Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.47

0.43

0.65

0.64

0.65

RBC Bioscience Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial					0.65	0.63	0.64	0.64	0.65

Competitive Comparison of RBC Bioscience's Debt-to-Asset

For the Biotechnology subindustry, RBC Bioscience's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RBC Bioscience's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RBC Bioscience's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where RBC Bioscience's Debt-to-Asset falls into.

RBC Bioscience Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

RBC Bioscience's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(74.764	+	412.598)	/	753.79
	=	0.65

RBC Bioscience's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(74.764	+	412.598)	/	753.79
	=	0.65

RBC Bioscience (ROCO:6848) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

RBC Bioscience Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of RBC Bioscience's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

RBC Bioscience (ROCO:6848) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RBC Bioscience Corp (ROCO:6848) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lane 235, Baoqiao Road, 3rd Floor, No. 132, New Taipei City, TWN, 23145

Website

https://www.rbcbioscience.com

RBC Bioscience Corp is a bio sciences company. Its products include Real Genomics, MagCore Automated Nucleic Acid Extractor, and MagCore Nucleic Acid Extraction KIT.

RBC Bioscience (ROCO:6848) Headlines

No Headlines